Response of Preterm Infants of Mothers Who Are Chronic Carriers of Both HBsAg and HBeAg to Pre-52 Containing Hepatitis 8 Vaccine (TGP 943) - A Preliminary Report

Abdul Hamid Sutohardjo

doi:10.14238/pi35.9-10.1995.211-5

Abdul Hamid Sutohardjo and Department of Child Psychiatry, Universitas Udayana Medical School/Sanglah Hospital, Denpasar, Bali

DOI: https://doi.org/10.14238/pi35.9-10.1995.211-5

Keywords: pre-S2 containing hepatitis B vaccine; hepatitis B vaccine; preterm infants; HBsAg; HBeAg; antibody

Abstract

This study aimed to examine the immunogenccity and protective efficacy of a pre-S2 containing hepatitis B vaccine (TGP 943, Takada, Japan) in 9 preterrn infants. A control group of preterm infants were given plasma derived hepatitis B vaccine (Korean Green Cross, Korea). All these preterm infants were born to both HBsAG and HBeAg posistive mothers and born in central General Hospital Sanglah Denpasar from January 3, 1992 to October 30, 1992. The gestational ages were 35-37 weeks and birth weights were 2000-2500 grams. The difference of the anti pre-S2 antibody between two groups of preterm infants was evident at month 6. Anti-HBs antibody response was almost same in the two groups of preterm infants. None in preterm infants in this study became positive for HBsAg during follow-up for at least 6 months. 2 of 8 preterm infants in control group become positive for HBsAg during follow up for a t least 6 months. Our study demonstrated a better anti pre-S2 antibody response and also comparable anti-Hbs antibody response in preterms infants vaccinated with a pre-S2 containing hepatitis B vaccine, compared with those with conventional plasma-derived vaccine.

References

1. Poovorawan Y, Sanpavat S, Pongpunler W, et al. Comparison of recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine. 1990; 8: 56-9.
2. Yu LL, Tam AYC, Ng KW< et al. Response of preterm infants to hepatitis B vaccinel. J Pediatr. 1992; 121: 962-5.
3. WHO Report. Meeting of task force on hepatitis B. Regional office for the Western Pacific Manila, Philippines. March, 1984.
4. Kane Mark A, John Clements, Dale Hu. The global control of hepatitis B. In: Assessment and management of risks associated with hepatitis B. Effectiveness of intervention. Philadelphia: Hanley & Belfus; 1990. p.75-92.
5. Hilleman Maurice R. The vaccine solution to the problem of human hepatitis B and it sequelae. In: Assessment and management of risks associated with hepatitis B: Effectiveness of intervention. Philadelphia: Hanley & Belfus, Inc.; 1990. p. 19-31.
6. Neurat AR, Kent SBH, Strick N, Parker A. The biological role of pre-S sequances for vaccine design. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
7. Adanomicz P, Cuoursaget P, Mazert MC, Goudeaou A, Lagarde D, Girard M. Pre-S antigenity and preS immunogenicity of a hepatitis B vaccine. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
8. Tiollais P, Michel ML, Millich DR, Chisari FV. Synthesis in chocells of Hepatitis B surface antigen particles containing the pre-S2 region expression product. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.
9. El Goulin. Importance of the production process for the preparation of a safe hepatitis B vaccine of optimal antigenic quality. Asian Symposisum on Strategies for Large Scale Hipatitis B Immunization. Hongkong; June 12-13, 1986.